Granted Patent
B2
US 12,599,676 · App. 19/072,750 · Granted Apr 14, 2026
Cytotoxic imidazo[1,2-A]pyridine compounds and their use in therapy
Inventors:
Robin Carr (London, GB); Roberto Solari (London, GB); Andrew Simon Bell (London, GB); Edward William Tate (London, GB); Roger Bonnert (Geneva, CH)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to compounds of formula (I) and related aspects.
Claims (26)
1 . A drug conjugate having the following formula:
or a salt thereof.
2 . The drug conjugate according to claim 1 , wherein the drug conjugate is conjugated to a functional group on an amino acid side chain.
3 . The drug conjugate according to claim 1 , wherein the drug conjugate is conjugated to a chain terminus.
4 . The drug conjugate according to claim 1 , wherein the drug conjugate is conjugated to a N-terminus.
5 . The drug conjugate according to claim 1 , wherein the drug conjugate, or salt thereof, is conjugated to a chain terminus or a functional group on an amino acid side chain at a functional group of the linker, wherein the functional group of the linker is maleimide.
6 . A pharmaceutical composition comprising the drug conjugate or salt thereof according to claim 5 , and a pharmaceutically acceptable carrier.
7 . A method for the treatment of cancer, which comprises administering to the subject a therapeutically effective amount of the drug conjugate or salt thereof according to claim 5 .
8 . The method according to claim 7 , wherein the cancer is breast cancer, bladder cancer, lung cancer, prostate cancer, kidney cancer, esophageal carcinoma, colorectal cancer, gallbladder carcinoma, brain tumor, lymphoma, leukemia or neuroblastoma.
9 . A drug conjugate having the following formula:
or a salt thereof.
10 . The drug conjugate according to claim 9 , wherein the drug conjugate is conjugated to a functional group on an amino acid side chain.
11 . The drug conjugate according to claim 9 , wherein the drug conjugate is conjugated to a chain terminus.
12 . The drug conjugate according to claim 9 , wherein the drug conjugate is conjugated to a N-terminus.
13 . The drug conjugate according to claim 9 , wherein the drug conjugate, or salt thereof, is conjugated to a chain terminus or a functional group on an amino acid side chain at a functional group of the linker, wherein the functional group of the linker is maleimide.
14 . A method for the treatment of cancer, which comprises administering to the subject a therapeutically effective amount of the drug conjugate or salt thereof according to claim 13 .
15 . The method according to claim 14 , wherein the cancer is breast cancer, bladder cancer, lung cancer, prostate cancer, kidney cancer, esophageal carcinoma, colorectal cancer, gallbladder carcinoma, brain tumor, lymphoma, leukemia or neuroblastoma.
16 . A drug conjugate having the following formula:
or a salt thereof.
17 . The drug conjugate according to claim 16 , wherein the drug conjugate is conjugated to a functional group on an amino acid side chain.
18 . The drug conjugate according to claim 16 , wherein the drug conjugate is conjugated to a chain terminus.
19 . The drug conjugate according to claim 16 , wherein the drug conjugate is conjugated to a N-terminus.
20 . The drug conjugate according to claim 16 , wherein the drug conjugate, or salt thereof, is conjugated to a chain terminus or a functional group on an amino acid side chain at a functional group of the linker, wherein the functional group of the linker is maleimide.
21 . A pharmaceutical composition comprising the drug conjugate or salt thereof according to claim 20 , and a pharmaceutically acceptable carrier.
22 . A method for the treatment of cancer, which comprises administering to the subject a therapeutically effective amount of the drug conjugate or salt thereof according to claim 20 .
23 . The method according to claim 22 , wherein the cancer is breast cancer, bladder cancer, lung cancer, prostate cancer, kidney cancer, esophageal carcinoma, colorectal cancer, gallbladder carcinoma, brain tumor, lymphoma, leukemia or neuroblastoma.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 13, 2025
From: CARR, ROBIN; SOLARI, ROBERTO; BONNERT, ROGER; BELL, ANDREW SIMON; TATE, EDWARD WILLIAM
To: MYRICX PHARMA LIMITED; IMPERIAL COLLEGE INNOVATIONS LIMITED
Reel/Frame 070495/0783 →
Priority Claims (4)
EP 22194959
· Sep 9, 2022
· regional
EP 22194984
· Sep 9, 2022
· regional
GB 2305541
· Apr 14, 2023
· national
GB 2305546
· Apr 14, 2023
· national
Continuity (2)
Continuation
PCTGB2023052319
· Sep 8, 2023
References Cited (194)
US 2917511A
· Bicking et al.
· 1959
[cited by applicant]
US 3050525A
· Bicking et al.
· 1962
[cited by applicant]
US 3145215A
· Kirchner et al.
· 1964
[cited by applicant]
US 3457269A
· Kirchner et al.
· 1969
[cited by applicant]
US 3678059A
· Gschwend et al.
· 1972
[cited by applicant]
US 3705175A
· Magdanyi et al.
· 1972
[cited by applicant]
US 4886808A
· King et al.
· 1989
[cited by applicant]
US 5017573A
· Kon et al.
· 1991
[cited by applicant]
US 5037844A
· Hamminga et al.
· 1991
[cited by applicant]
US 5190953A
· Munson, Jr. et al.
· 1993
[cited by applicant]
US 5246945A
· Kikuchi et al.
· 1993
[cited by applicant]
US 5665725A
· Moltzen et al.
· 1997
[cited by applicant]
US 5684003A
· Kikuchi et al.
· 1997
[cited by applicant]
US 5798367A
· Catlow et al.
· 1998
[cited by applicant]
US 5861414A
· Allen et al.
· 1999
[cited by applicant]
US 5914405A
· Wilson
· 1999
[cited by applicant]
US 5985867A
· Rodgers et al.
· 1999
[cited by applicant]
US 6069152A
· Schaus et al.
· 2000
[cited by applicant]
US 6096746A
· Suzuki et al.
· 2000
[cited by applicant]
US 6303625B1
· Hoekstra et al.
· 2001
[cited by applicant]
US 6376491B1
· Aoki et al.
· 2002
[cited by applicant]
US 6458781B1
· Connor et al.
· 2002
[cited by applicant]
US 8557841B2
· Yu et al.
· 2013
[cited by applicant]
US 20020119972A1
· Leftheris et al.
· 2002
[cited by applicant]
US 20020161022A1
· Reich et al.
· 2002
[cited by applicant]
US 20030096838A1
· McClure et al.
· 2003
[cited by applicant]
US 20030109550A1
· Clare et al.
· 2003
[cited by applicant]
US 20030149034A1
· Lee et al.
· 2003
[cited by applicant]
US 20040014764A1
· Smith et al.
· 2004
[cited by applicant]
US 20060135589A1
· Berdino et al.
· 2006
[cited by applicant]
US 20060142345A1
· Kephart et al.
· 2006
[cited by applicant]
US 20060281789A1
· Shiotsu et al.
· 2006
[cited by applicant]
US 20070197522A1
· Edwards et al.
· 2007
[cited by applicant]
US 20090209577A1
· Rucker et al.
· 2009
[cited by applicant]
US 20090215817A1
· Rucker et al.
· 2009
[cited by applicant]
US 20090247504A1
· Churcher et al.
· 2009
[cited by applicant]
US 20090291968A1
· Georges et al.
· 2009
[cited by applicant]
US 20100113421A1
· Williams et al.
· 2010
[cited by applicant]
US 20110124626A1
· Pooni et al.
· 2011
[cited by applicant]
US 20130310373A1
· Matsushima et al.
· 2013
[cited by applicant]
US 20140227284A1
· Berthiaume et al.
· 2014
[cited by applicant]
US 20140378474A1
· Flohr et al.
· 2014
[cited by applicant]
US 20220071960A1
· Tate
· 2022
[cited by examiner]
US 20220411431A1
· Bell et al.
· 2022
[cited by applicant]
EP 0261964A2
· 1988
[cited by applicant]
EP 0494774A1
· 1992
[cited by applicant]
EP 0517984A1
· 1992
[cited by applicant]
EP 0623621A1
· 1994
[cited by applicant]
EP 0765873B1
· 2002
[cited by applicant]
EP 1674464A1
· 2006
[cited by applicant]
GB 2208862A
· 1989
[cited by applicant]
GB 2345486A
· 2000
[cited by applicant]
JP 63310891A
· 1988
[cited by applicant]
JP 03223280A
· 1991
[cited by applicant]
JP 05230057A
· 1993
[cited by applicant]
JP 06135960A
· 1994
[cited by applicant]
JP 11279156A
· 1999
[cited by applicant]
WO 9204025A1
· 1992
[cited by applicant]
WO 9205174A1
· 1992
[cited by applicant]
WO 9303725A1
· 1993
[cited by applicant]
WO 9961426A1
· 1999
[cited by applicant]
WO 0037464A2
· 2000
[cited by applicant]
WO 0063215A2
· 2000
[cited by applicant]
WO 0102369A2
· 2001
[cited by applicant]
WO 2004077682A2
· 2004
[cited by applicant]
WO 2005014554A1
· 2005
[cited by applicant]
WO 2008040995A1
· 2008
[cited by applicant]
WO 2008153858A1
· 2008
[cited by applicant]
WO 2010026365A1
· 2010
[cited by applicant]
WO 2011019738A1
· 2011
[cited by applicant]
WO 2012095781A1
· 2012
[cited by applicant]
WO 2013083991A1
· 2013
[cited by applicant]
WO 2013133556A1
· 2013
[cited by applicant]
WO 2017001812A1
· 2017
[cited by applicant]
WO 2017011907A1
· 2017
[cited by applicant]
WO 2020128473A1
· 2020
[cited by applicant]
WO 2020128475A1
· 2020
[cited by applicant]
WO 2021008512A1
· 2021
[cited by applicant]
WO 2022058745A3
· 2022
[cited by applicant]
WO 2022090746A1
· 2022
[cited by applicant]
WO 2024052685A1
· 2024
[cited by applicant]
WO 2025007800A1
· 2025
[cited by applicant]
Rackham et al., “Discovery of Novel and Ligand-Efficient Inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferase,” Journal of Medicinal Chemistry, 2013, 56, pp. 371-375.
[cited by applicant]
Rackham et al., “Discovery of high affinity inhibitors of Leishmania donovani N-myristoyltransferase,” Med. Chem. Commun., 2015, DOI: 10.1039/c5md00241a. (6 pages).
[cited by applicant]
Ramljak et al., “Cellular N-myristoyltransferasees play a crucial picornavirus genus-specific role in viral assembly, virion maturation, and infectivity”, PLoS Pathogens, vol. 14, No. 8, Aug. 6, 2018, pp. 1-39.
[cited by applicant]
Resh, M., “Interaction of tyrosine kinase oncoproteins with cellular membranes,” Biochimica et Biophysica Acta, 1993, 1155, pp. 307-322.
[cited by applicant]
Robinson et al., “Identification and structure solution of fragment hits against kinetoplastid N-myristoyltransferase,” Acta Cryst., 2015, F71, pp. 586-593.
[cited by applicant]
Rudnick et al., “Kinetic and Structural Evidence for a Sequential Ordered Bi Bi mechanism of Catalysis by
[cited by applicant]
Sheng et al., “Homology modelling and molecular dynamics simulation of N-myristoyltransferase from protozoan parasites: active site characterization and insights into reational inhibito design,” J Comput Aided Mol Des, …
[cited by applicant]
Sheng et al., “Design, synthesis and antifungal activity of isosteric analogues of benzoheterocyclic N-myristoyltransferase inhibitors,” European Journal of Medicinal Chemistry, 2010, 45, pp. 3531-3540.
[cited by applicant]
Sikorski et al., “Selective Peptidic and Peptidomimetic Inhibitors of Candida albicans MyristoylCoA : Protein N-Myristoyltransferase: A New Approach to Antifungal Therapy,” Biopolymers, 1997, 43, pp. 43-71.
[cited by applicant]
Snyder et al., “The Synthesis of an Indazole Analog of DL-Tryptophan,” JACS, 1952, vol. 74, pp. 2009-2012.
[cited by applicant]
Snyder et al., “The Synthesis of DL-alpha-Amino-beta-6-methyl-3-indazolyl)-propionic Acid,” JACS, 1954, vol. 76, 1298-1301.
[cited by applicant]
Sogabe et al., “Crystal Structures of Candida albicans N-Myristoyltransferase with two Distinct inhibitors,” Chemistry & Biology, 2002, vol. 9, pp. 1119-1128.
[cited by applicant]
Tate et al., “Peptide-based inhibitors of N-myristoyl transferase generated from a lipid/combinatorial peptide chimera library,” Signal Transduction, 2006, 6, pp. 60-166.
[cited by applicant]
Wang et al., “Expeditious one-pot synthesis of C3-piperazinyl-substituted quinolines: key precursors to potent c-Met inhibitors,” Org. Biomol. Chem., 2011, 9, pp. 5930-5933.
[cited by applicant]
Wang et al., “The role of N-myristoyltransferase 1 in tumour development”, Annals of Medicine, Vo. 55, No. 1, pp. 1422-1430.
[cited by applicant]
Wiegand et al., “The Candida albicans Myristoyl-CoA:Protein N-Myristoyltransferase Gene,” The Journal of Biological Chemistry, 1992, vol. 267, No. 12, pp. 8591-8598.
[cited by applicant]
Wright et al., “Validation of N-Myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach,” Nature Chemistry, 2013, DOI: 10.1038/NCHEM.1830, pp. 1-10.
[cited by applicant]
Wu et al., “A versatile linkage strategy for solid-phase synthesis of N,N-dimethyltryptamines and β-carbolines”, Organic Letters, Vo. 4, No. 23, pp. 4033-4036.
[cited by applicant]
Wu et al., “Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: Synthesis and SAR study as tyrosine kinase c-Met inhibitors,” Bioorganic and Medicinal chemistry Letters 22, 2012, pp. 6368-6372.
[cited by applicant]
Yamazaki et al., “Synthesis of potent and selective inhibitors of Candida albicans N-myristoyltransferase based on benzothiazole structure,” Bioorganic & medicinal Chemistry 13, 2005, pp. 2509-2522.
[cited by applicant]
Yu et al., “Design and Synthesis of Inhibitors of Plasmodium falciparum N-Myristoyltransferase, A Promising target for Antimalarial Drug Discover,” Journal of Medicinal Chemistry, 2012, 55, pp. 8879-8890.
[cited by applicant]
Yu et al., “Discovery of pyridyl-based inhibitors of Plasmodium falciparum N-myristoyltransferase .” Med. Chem. Commun., 2015,: DOI: 10.1039/c5md00242g, (6pages).
[cited by applicant]
Armour, D., “Discovery of a novel Series of Non-Peptidic Fungal N-Myristoyl Transferase (NMT) Inhibitors,” Slides from Pfizer, 221 ACS meeting, 2001, MEDI 349, (21 pages).
[cited by applicant]
Abstract Book, “Emerging Paradigms in Anti-Infective Drug Design,” London School of Hygiene and Tropical Medicine, British Society for Parasitology and Royal Society of Chemistry (Biological and Medicinal Chemistry Sect…
[cited by applicant]
Basta et al., “Modeling of human rhinovirus C capsid suggests a novel topography with insights on receptor preference and immunogenicity,” Virology, 2014, 448, pp. 176-144.
[cited by applicant]
Bell et al., “Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs,” PLOS Neglected Tropical Diseases, 2012, vol. 6, Issue 4, e1625, pp. …
[cited by applicant]
Bell et al., Slides from “Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs,” Emerging Paradigms in Anti-Infective Drug Design, London…
[cited by applicant]
Bell et al., “Discovery of Fungicidal N-Myristoyl Transferase (NMT) Inhibitors,” Slides from Pfizer, 221 ACS meeting, 2001, MEDI 350, (20 pages).
[cited by applicant]
Boezio, et al., “Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors,” Bioorganic & Medicinal Chemistry Letters 19, 2009, pp. 6307-6312.
[cited by applicant]
Bowyer et al., “Molecules incorporating a benzothiazole core scaffold inhibit the N-myristoyltransferase of Plasmodium falciparum,” Biochem. J., 2007, 408, pp. 173-180, DOI: 10.1042/BJ20070692 (8 pages).
[cited by applicant]
Bowyer et al., “N-Myristoyltransferase: a Prospective Drug Target for Protozoan Parasites,” ChemMedChem, 2008, 3, pp. 402-408, DOI: 10.1002/cmdc.200700301 (7 pages).
[cited by applicant]
Brand et al., “Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors,” Journal of Medicinal Chemistry, 2012, 55, pp. 140-152.
[cited by applicant]
Brand et al., “Lead Optimizatin of a Pyrazole Sulfonamide Series of Trypanosoma brucei N-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Huma…
[cited by applicant]
Brannigan et al., “Diverse modes of binding in structures of Leishmania major N-myristoyltransferase with selective inhibitors,” IUCrJ, 2014, 1, pp. 250-266.
[cited by applicant]
Brannigan et al., “N-Myristoyltransferase from Leishmania donovani: Structural and Functional Characterisation of a Potential Drug Target for Visceral Leishmaniasis.” J. Mol. Biol. 2010, 396, pp. 985-999.
[cited by applicant]
Bryant et al., “Myristoylation-dependent replication and assembly of human immunodeficiency virus 1,” Proc. Natl. Acad. Sci. USA, 1990, vol. 87, pp. 523-527.
[cited by applicant]
Davis et al., “Recombinant VP4 of Human Rhinovirus Induces Permeability in Model Membranes,” Journal of Virology, 2008, vol. 82, No. 8, pp. 4169-4174.
[cited by applicant]
Devadas et al., “Design and Synthesis of Novel Imidazole-Substituted Dipeptide Amides as Potent and Selective Inhibitors of Candida albicans MyristoylCoA:Protein N-Myristoyltransferase and Identification of Related Trip…
[cited by applicant]
Devadas et al., “Design and Synthesis of Potent and Selective Dipeptide Inhibitors of Candida albicans Myristoyl-CoA: Protein N-Myristoyltransferase,” Journal of Medicinal Chemistry, 1995, vol. 38, No. 11, pp. 1837-1840.
[cited by applicant]
Duronio et al., “Disruption of the Yeast N-Myristoyl Transferase gene Causes Recessive Lethality,” Science, 1989, vol. 243, pp. 796-800.
[cited by applicant]
Ebara et al., “FTR1335 Is a Novel Synthetic Inhibitor of Candida albicans N-Myristoyltransferase with Fungicidal Activity,” Biol. Pharm. Bull., 2005, vol. 28, No. 4, pp. 591-595.
[cited by applicant]
Ebiike et al., “Design and Synthesis of Novel Benzofurans as a New Class of Antifungal Agents Targeting Fungal N-Myristoyltransferase. Part 2,” Bioorganic & Medicinal Chemistry Letters 12, 2002, pp. 607-610.
[cited by applicant]
Fang et al., “N-Myristoyltransferase Is a Cell Wall Target in Aspergillus fumigatus,” ACS Chem. Biol., 2015, 10, pp. 1425-1434.
[cited by applicant]
Farazi et al., “The Biology and Enzymology of Protein N-Myristoylation,” The Journal of Biological Chemistry, 2001, vol. 276, No. 43, pp. 39501-39504.
[cited by applicant]
Frearson et al., “N-myristoyltransferase inhibitors as new leads to treat sleeping sickness,” Nature, 2010, vol. 464, pp. 728-732 (7 pages).
[cited by applicant]
Galvin et al., “A Target Repurposing Approach Identifies N-myristoyltransferase as a New Candidate Drug Target in Filarial Nematodes,” PLOS Neglected Tropical Diseases, 2014, vol. 8, Issue 9, e3145, pp. 1-13.
[cited by applicant]
Giang et al., “A Second Mammalian N-Myristoyltransferase,” The Journal of Biological Chemistry, 1998, vol. 273, No. 12, pp. 6595-6598.
[cited by applicant]
Goncalves et al., “A fluorescence-based assay for N-Myristoyltransferase activity,” Anal Biochem., 2012, 421(1), pp. 1-7.
[cited by applicant]
Goncalves et al., “Discovery of Plasmodium vivax N-Myristoyltransferase Inhibitors: Screening, Synthesis, and Structural Characterization of their Binding Mode,” Journal of Medicinal Chemistry, 2012, 55, pp. 3578-3582.
[cited by applicant]
Gottlinger et al., “Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1,” Proc. Natl. Acad. Sci. USA, 1989, vol. 86, pp. 5781-5785.
[cited by applicant]
Grundt et al., “Analogues of the dopamine D2 receptor antagonist L741, 626: Binding, function, and SAR,” Bioorganic & medicinal Chemistry Letters 17, 2007, pp. 745-749.
[cited by applicant]
Gunaratne et al., “Characterization of N-myristoyltransferase from Plasmodium falciparum,” Biochem. J., 2000, 348, pp. 459-463.
[cited by applicant]
Herrera et al., “Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of Trypanosoma cruzi,” PLOS Neglected Tropical Diseases, 2016, DOI: 10.1371/journal.pntd.0004540, pp. …
[cited by applicant]
Hutton et al., “Structure-Based Design of Potent and Selective Leishmania N-Myristoyltransferase Inhibitors,” Journal of Medicinal Chemistry, 2014, 57, pp. 8664-8670.
[cited by applicant]
International Search Report and Written Opinion issued in corresponding International Patent Application No. PCT/GB2023/052319 dated Jan. 4, 2024 (11 pages).
[cited by applicant]
Johnson et al., “Genetic and Biochemical Studies of Protein N-Myristoylation,” Annu. Rev. Biochem., 1994, 63, pp. 868-914.
[cited by applicant]
Kawasaki et al., “Design and Synthesis of Novel Benzofurans as a New Class of Antifungal Agents Targeting Fungal N-Myristoyltransferase. Part 3,” Bioorganic & Medicinal Chemistry Letters 13, 2003, pp. 87-91.
[cited by applicant]
Khongorzul et al., “Antibody-Drug Conjugates: A Comprehensive Review”, Molecular Cancer Research, vol. 18, No. 1, pp. 3-19.
[cited by applicant]
Lee et al., “Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors,” Bioorganic & Medicinal Chemistry Letters 18, 2008, pp. 2292-2295.
[cited by applicant]
Liu et al., “Novel benzodithiazole derivatives with broad antifungal spectrum: design, synthesis and structure-activity relationships,” Med. Chem. Commun., 2013, 4, pp. 1551-1651.
[cited by applicant]
Lodge et al., “Comparison of Myristoyl-CoA: Protein N-Myristolytransferases from Three Pathogenic Fungi: Cryptococcus neoformans, Histoplasma capsulatum, and Candida albicans,” the Journal of Biological Chemistry, 1994,…
[cited by applicant]
Lueg et al., “N-myristoyltransferase inhibition is synthetic lethal in MYC-deregulated cancers,” bioRxiv, Mar. 20, 2021, pp. 1-25.
[cited by applicant]
Masubuchi et al., “Design and Synthesis of Novel Benzofurans as a New Class of Antifungal Agents Targeting Fungal N-Myrisyoyltransferase. Part 1,” Bioorganic & Medicinal Chemistry Letters 11, 2001, pp. 1833-1837.
[cited by applicant]
Masubuchi et al., “Synthesis and Biological Activities of Benzofuran Antifungal Agents Targeting Fungal N-Myristoyltransferase,” Bioorganic and Medicinal Chemistry 11, 2003, pp. 463-4478.
[cited by applicant]
McIlhinney et al., “Immunocytochemical Characterization and Subcellular Localization of Human Myristoyl-CoA: Protein N-Myristoyltransferase in Hela Cells,” Experimental Cell Research, 1996, 223, pp. 348-356.
[cited by applicant]
Mousnier et al., “Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus,” Nature Chemistry, vol. 10, No. 6, May 14, 2018, 18 pages.
[cited by applicant]
Music et al., “Synthesis of Benzylaminomethyl and aminomethyl substituted fused 1,2,4-triazoles,” Synthetic Communications, 2001, 31(10), pp. 15111519.
[cited by applicant]
Music et al., “Reaction of Acylglycines with Heteroarylhydrazines,” heterocyclic Communications, 2005, vol. 11, Nos. 3-4, pp. 321-324.
[cited by applicant]
Nagarajan et al., “Conformationally Constrained [p-(omega-Aminoalkyl)phenacetyl]-L-seryl-L-lysyl Dipeptide Amides as Potent Peptidomimietic Inhibitors of Candida albicans and Human Myristoyl-CoA:protein N-Myristoyl Tran…
[cited by applicant]
Olaleye et al., “Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites,” Organic & Biomolecular Chemistry, 2014, DOI: 10.1039/c4ob01669f, (6 pages).
[cited by applicant]
Panethymitaki et al., “Characterization and selective inhibition of myristoyl-CoA:protein N-myristoyltransferase from Trypansoma brucei and Leishmania major,” Biochem. J., 2006, 396, pp. 277-285.
[cited by applicant]
Price et al., “Myristoyl-CoA: Protein N-Myristoyltransferase, an Essential Enzyme and Potential Drug Target in Kintoplastid Parasites,” The Journal of Biological Chemistry, 2003, vol. 278, No. 9, pp. 7206-7214.
[cited by applicant]